

## Jivi® (antihemophilic factor [recombinant], PEGylated-aucl) – Expanded indication

- On May 19, 2025, <u>Bayer announced</u> the FDA approval of <u>Jivi (antihemophilic factor [recombinant]</u>, <u>PEGylated-aucl)</u>, for use in previously treated adults and <u>pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency) for:
  </u>
  - On-demand treatment and control of bleeding episodes
  - Perioperative management of bleeding
  - Routine prophylaxis to reduce the frequency of bleeding episodes.
- Jivi was previously approved for this indication in pediatric patients 12 years of age and older.
- The use of Jivi for the expanded indication was supported by evidence from three clinical studies, Study 2 (PROTECT VIII), Study 3 (PROTECT Kids) and Study 4 (Alfa-PROTECT), which included 108 pediatric patients 2 to < 12 years of age and 12 pediatric patients 12 to < 17 years of age.</li>
- Refer to the Jivi drug label for complete dosing and administration recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.